Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Apyx Medical (APYX) and Agilent (A)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Healthequity (HQY – Research Report), Apyx Medical (APYX – Research Report) and Agilent (A – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Healthequity (HQY)
In a report released today, Stan Berenshteyn from Wells Fargo reiterated a Buy rating on Healthequity, with a price target of $125.00. The company’s shares closed last Tuesday at $78.50.
According to TipRanks.com, Berenshteyn ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Healthequity with a $110.60 average price target, implying a 40.1% upside from current levels. In a report issued on March 5, KeyBanc also maintained a Buy rating on the stock with a $125.00 price target.
See the top stocks recommended by analysts >>
Apyx Medical (APYX)
In a report released today, Sam Eiber from BTIG upgraded Apyx Medical to Buy, with a price target of $6.00. The company’s shares closed last Tuesday at $3.45.
According to TipRanks.com, Eiber is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Apyx Medical with a $6.00 average price target, a 70.9% upside from current levels. In a report issued on March 2, Craig-Hallum also maintained a Buy rating on the stock.
Agilent (A)
In a report released today, Patrick B Donnelly from Citi maintained a Buy rating on Agilent, with a price target of $185.00. The company’s shares closed last Tuesday at $115.43.
According to TipRanks.com, Donnelly is a 3-star analyst with an average return of
Agilent has an analyst consensus of Strong Buy, with a price target consensus of $163.62, representing a 41.7% upside. In a report issued on February 26, TipRanks – PerPlexity also upgraded the stock to Buy with a $138.00 price target.
